$VYNE
VYNE Therapeutics Inc. Stock $vyne

$vyne Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-K Financial Statement

#000156604421000010 Filed on March 04, 2021

Income Statement

Concept	2020 Q4	2020 Q3	2020 Q2
Revenue	$4.286M	$3.269M	$11.69M
YoY Change	3074.81%
Cost Of Revenue	$24.88M	$26.76M	$178.9M
YoY Change		15.35%	823.94%
Gross Profit	-$20.60M	-$23.49M	-$167.2M
YoY Change	-15357.04%	1.26%	763.56%
Gross Profit Margin	-480.56%	-718.6%	-1430.33%
Selling, General & Admin	$17.90M	$19.77M	$26.46M
YoY Change	76.01%	83.92%	288.93%
% of Gross Profit
Research & Development	$7.840M	$6.623M	$13.12M
YoY Change	-33.33%	-46.81%	4.48%
% of Gross Profit
Depreciation & Amortization	$90.00K	$60.00K	$100.0K
YoY Change	-145.0%	-40.0%	25.0%
% of Gross Profit
Operating Expenses	$25.75M	$26.39M	$39.58M
YoY Change	17.41%	51.43%	129.89%
Operating Profit	-$21.99M	-$23.49M	-$167.2M
YoY Change	-41.25%	1.26%	763.56%
Interest Expense	-$1.160M	$1.092M	$1.070M
YoY Change	-367.9%	91.24%	44.79%
% of Operating Profit
Other Income/Expense, Net	-$30.00K	-$130.0K	$548.0K
YoY Change		-122.77%	-25.85%
Pretax Income	-$23.18M	-$24.71M	-$167.7M
YoY Change	7.81%	6.7%	782.95%
Income Tax	$0.00	$1.000K	-$259.0K
% Of Pretax Income
Net Earnings	-$23.18M	-$24.71M	-$167.4M
YoY Change	7.82%	6.71%	781.59%
Net Earnings / Revenue	-540.83%	-756.01%	-1432.58%
Basic Earnings Per Share		-$0.59	-$4.83
Diluted Earnings Per Share	-$548.4K	-$0.59	-$4.83
COMMON SHARES
Basic Shares Outstanding	167.9M shares	41.93M shares	34.66M shares
Diluted Shares Outstanding		41.93M shares	34.66M shares

Balance Sheet

Concept	2020 Q4	2020 Q3	2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$58.59M	$76.00M	$99.12M
YoY Change	-3.06%	-16.85%	-9.4%
Cash & Equivalents	$57.56M	$72.96M	$96.51M
Short-Term Investments	$1.027M	$3.046M	$2.609M
Other Short-Term Assets	$6.500M	$7.400M	$6.600M
YoY Change	-65.97%	252.38%	78.38%
Inventory	$7.404M	$6.650M	$5.801M
Prepaid Expenses
Receivables	$15.82M	$11.19M	$6.407M
Other Receivables	$0.00	$0.00	$4.000M
Total Short-Term Assets	$87.26M	$98.16M	$119.3M
YoY Change	14.19%	5.07%	5.45%
LONG-TERM ASSETS
Property, Plant & Equipment	$555.0K	$2.744M	$2.811M
YoY Change	-80.76%	2328.32%	2096.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$4.345M	$4.600M	$6.200M
YoY Change	2517.47%	2200.0%	6100.0%
Total Long-Term Assets	$6.483M	$9.521M	$11.55M
YoY Change	36.63%	202.54%	819.01%
TOTAL ASSETS
Total Short-Term Assets	$87.26M	$98.16M	$119.3M
Total Long-Term Assets	$6.483M	$9.521M	$11.55M
Total Assets	$93.74M	$107.7M	$130.8M
YoY Change	15.5%	11.5%	14.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.800M	$4.600M	$10.00M
YoY Change	27.29%	53.74%	112.59%
Accrued Expenses	$11.45M	$12.13M	$8.812M
YoY Change	238.72%	112.13%	35.84%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00
YoY Change
Total Short-Term Liabilities	$21.77M	$23.19M	$24.23M
YoY Change	-25.78%	145.37%	103.53%
LONG-TERM LIABILITIES
Long-Term Debt	$33.17M	$33.02M	$32.92M
YoY Change	1.37%
Other Long-Term Liabilities	$1.600M	$2.000M	$2.200M
YoY Change	6.67%	1900.0%	633.33%
Total Long-Term Liabilities	$34.48M	$34.98M	$35.08M
YoY Change	0.66%	34875.0%	11594.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.77M	$23.19M	$24.23M
Total Long-Term Liabilities	$34.48M	$34.98M	$35.08M
Total Liabilities	$56.25M	$58.17M	$59.31M
YoY Change	-11.54%	507.55%	385.9%
SHAREHOLDERS EQUITY
Retained Earnings	-$566.2M	-$543.0M	-$518.3M
YoY Change	82.3%	233.45%	255.03%
Common Stock	$4.000K	$17.00K	$17.00K
YoY Change	300.0%	-99.99%	-99.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$37.49M	$49.52M	$71.53M
YoY Change
Total Liabilities & Shareholders Equity	$93.74M	$107.7M	$130.8M
YoY Change	15.5%	11.5%	14.39%

Cashflow Statement

Concept	2020 Q4	2020 Q3	2020 Q2
OPERATING ACTIVITIES
Net Income	-$23.18M	-$24.71M	-$167.4M
YoY Change	7.82%	6.71%	781.59%
Depreciation, Depletion And Amortization	$90.00K	$60.00K	$100.0K
YoY Change	-145.0%	-40.0%	25.0%
Cash From Operating Activities	-$25.37M	-$23.64M	-$35.86M
YoY Change	81.86%	8.49%	181.92%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$70.00K
YoY Change	-100.0%	-100.0%	-77.42%
Acquisitions
YoY Change
Other Investing Activities	$2.000M	$0.00	$21.20M
YoY Change	-57.36%	-100.0%	-35.93%
Cash From Investing Activities	$2.000M	$0.00	$21.13M
YoY Change	-63.83%	-100.0%	-35.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	7.980M	80.00K	53.61M
YoY Change	-134.76%	-99.71%
NET CHANGE
Cash From Operating Activities	-25.37M	-23.64M	-35.86M
Cash From Investing Activities	2.000M	0.000	21.13M
Cash From Financing Activities	7.980M	80.00K	53.61M
Net Change In Cash	-15.39M	-23.56M	38.88M
YoY Change	-50.96%	-1702.72%	93.92%
FREE CASH FLOW
Cash From Operating Activities	-$25.37M	-$23.64M	-$35.86M
Capital Expenditures	$0.00	$0.00	-$70.00K
Free Cash Flow	-$25.37M	-$23.64M	-$35.79M
YoY Change	71.42%	10.57%	188.4%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001566044
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-38356
CY2020	dei	Entity Registrant Name EntityRegistrantName	VYNE THERAPEUTICS INC.
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-3757789
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	520 U.S. Highway 22, Suite 204
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Bridgewater
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	08807
CY2020	dei	City Area Code CityAreaCode	800
CY2020	dei	Local Phone Number LocalPhoneNumber	755-7936
CY2020	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001
CY2020	dei	Trading Symbol TradingSymbol	VYNE
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2020	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	true
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2020	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	245000000.0	USD
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	51329179	shares
CY2020Q4	vyne	Liquidation Of Subsidiary Intellectual Property Acquired Taxable Gain LiquidationOfSubsidiaryIntellectualPropertyAcquiredTaxableGain	163000000.0	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	57563000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43759000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	855000	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	825000	USD
CY2020Q4	us-gaap	Other Short Term Investments OtherShortTermInvestments	0	USD
CY2019Q4	us-gaap	Other Short Term Investments OtherShortTermInvestments	12102000	USD
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	1027000	USD
CY2019Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	16246000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	135000	USD
CY2020Q4	us-gaap	Restricted Investments Current RestrictedInvestmentsCurrent	0	USD
CY2019Q4	us-gaap	Restricted Investments Current RestrictedInvestmentsCurrent	434000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15819000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4591000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1557000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	7404000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	1356000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	87259000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	76414000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	555000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2885000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1583000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1694000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4345000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	166000	USD
CY2020Q4	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	312000	USD
CY2019Q4	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	424000	USD
CY2020Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	6483000	USD
CY2019Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	4745000	USD
CY2020Q4	us-gaap	Assets Assets	93742000	USD
CY2019Q4	us-gaap	Assets Assets	81159000	USD
CY2020Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	4780000	USD
CY2019Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	19352000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11452000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3381000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4360000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5231000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	757000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1092000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	104000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	270000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21453000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	29326000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	853000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	653000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	33174000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	32725000	USD
CY2020Q4	us-gaap	Other Liabilities OtherLiabilities	457000	USD
CY2019Q4	us-gaap	Other Liabilities OtherLiabilities	456000	USD
CY2020Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	34796000	USD
CY2019Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	34258000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	56249000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	63584000	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43205221	shares
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	93742000	USD
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43205221	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9120078	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9120078	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	603685000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	328156000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-566196000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-310587000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	5000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	37493000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	17575000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	81159000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20993000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	443000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3595000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1392000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	USD
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	USD
CY2019	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	43533000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	51202000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	64474000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	89543000	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	45114000	USD
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	14013000	USD
CY2020	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	54345000	USD
CY2018	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	USD
CY2020	vyne	Contingent Stock Consideration Remeasurement Gain Loss ContingentStockConsiderationRemeasurementGainLoss	-84726000	USD
CY2019	vyne	Contingent Stock Consideration Remeasurement Gain Loss ContingentStockConsiderationRemeasurementGainLoss	0	USD
CY2018	vyne	Contingent Stock Consideration Remeasurement Gain Loss ContingentStockConsiderationRemeasurementGainLoss	0	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	272147000	USD
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	96316000	USD
CY2018	us-gaap	Costs And Expenses CostsAndExpenses	78487000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-252546000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-95873000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-74892000	USD
CY2020	us-gaap	Interest Expense InterestExpense	4390000	USD
CY2019	us-gaap	Interest Expense InterestExpense	921000	USD
CY2018	us-gaap	Interest Expense InterestExpense	0	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1110000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1440000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-941000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-255826000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-95354000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-73951000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-258000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-176000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	212000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-255568000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-95178000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-74163000	USD
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	7.88
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	11.22
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	11.47
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	32418000	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	8485000	shares
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6466000	shares
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-255568000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-95178000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-74163000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	47000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	59000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	6000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	2000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	-5000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax	0	USD
CY2019	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax	3000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax	-74000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax	0	USD
CY2019	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax	0	USD
CY2018	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax	-60000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-5000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	48000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	50000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-255573000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-95130000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-74113000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	68601000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-74113000	USD
CY2018	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	39000	USD
CY2018	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	16131000	USD
CY2018	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	840000	USD
CY2018	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	47000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	5320000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	92182000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-95130000	USD
CY2019	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	359000	USD
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	15011000	USD
CY2019	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	617000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	4895000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	17575000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-255573000	USD
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	554000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	18100000	USD
CY2020	vyne	Deemed Dividend To Warrants Holders Due To Warrant Modification DeemedDividendToWarrantsHoldersDueToWarrantModification	0	USD
CY2020	vyne	Share Based Payment Modification Of Terms Incremental Compensation Modification Of Terms Incremental Compensation Cost Reclassified Adjustment ShareBasedPaymentModificationOfTermsIncrementalCompensationModificationOfTermsIncrementalCompensationCostReclassifiedAdjustment	975000	USD
CY2020	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	196170000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	37493000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-74163000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-373000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-255568000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-95178000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	341000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	350000	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	319000	USD
CY2020	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	54345000	USD
CY2019	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	USD
CY2018	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	USD
CY2020	vyne	Contingent Stock Consideration Remeasurement Gain Loss ContingentStockConsiderationRemeasurementGainLoss	-84726000	USD
CY2019	vyne	Contingent Stock Consideration Remeasurement Gain Loss ContingentStockConsiderationRemeasurementGainLoss	0	USD
CY2018	vyne	Contingent Stock Consideration Remeasurement Gain Loss ContingentStockConsiderationRemeasurementGainLoss	0	USD
CY2020	vyne	Gain Loss On Sale And Disposition Of Fixed Assets GainLossOnSaleAndDispositionOfFixedAssets	-2101000	USD
CY2019	vyne	Gain Loss On Sale And Disposition Of Fixed Assets GainLossOnSaleAndDispositionOfFixedAssets	-18000	USD
CY2018	vyne	Gain Loss On Sale And Disposition Of Fixed Assets GainLossOnSaleAndDispositionOfFixedAssets	-44000	USD
CY2020	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	142000	USD
CY2019	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	357000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	308000	USD
CY2018	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-201000	USD
CY2020	vyne	Increase Decrease In Employee Severance Liability Net Of Retirement Fund Profits IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits	-112000	USD
CY2019	vyne	Increase Decrease In Employee Severance Liability Net Of Retirement Fund Profits IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits	57000	USD
CY2018	vyne	Increase Decrease In Employee Severance Liability Net Of Retirement Fund Profits IncreaseDecreaseInEmployeeSeveranceLiabilityNetOfRetirementFundProfits	-70000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	18100000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	4895000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	5320000	USD
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	542000	USD
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-140000	USD
CY2018	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-43000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	17138000	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	4171000	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	131000	USD
CY2018	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	14000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-12975000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	18053000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	238000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6048000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1356000	USD
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	1000	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-258000	USD
CY2018	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-274000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-137082000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-73394000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-68664000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	113000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1058000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	567000	USD
CY2020	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2019	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	40000	USD
CY2018	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	10000	USD
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	USD
CY2019	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	44964000	USD
CY2018	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	77652000	USD
CY2020	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	38641000	USD
CY2019	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	USD
CY2018	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	USD
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	50579000	USD
CY2019	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	87851000	USD
CY2018	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	66454000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	89107000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	41869000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11755000	USD
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2019	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2018	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	840000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	310000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	365000	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	47000	USD
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	141000	USD
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	32000	USD
CY2018	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	61639000	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	13714000	USD
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	91487000	USD
CY2020	vyne	Proceeds From Debt Financing And Issuance Of Warrants Net Of Issuance Costs ProceedsFromDebtFinancingAndIssuanceOfWarrantsNetOfIssuanceCosts	0	USD
CY2019	vyne	Proceeds From Debt Financing And Issuance Of Warrants Net Of Issuance Costs ProceedsFromDebtFinancingAndIssuanceOfWarrantsNetOfIssuanceCosts	33903000	USD
CY2018	vyne	Proceeds From Debt Financing And Issuance Of Warrants Net Of Issuance Costs ProceedsFromDebtFinancingAndIssuanceOfWarrantsNetOfIssuanceCosts	0	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	61808000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	47950000	USD
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	92374000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	13833000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	16425000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	11955000	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	41000	USD
CY2018	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-43000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	44584000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28118000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16206000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	58418000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	44584000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28118000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	57563000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43759000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27868000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	855000	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	825000	USD
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	250000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	58418000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	44584000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28118000	USD
CY2019	us-gaap	Other Significant Noncash Transaction Value Of Consideration Received1 OtherSignificantNoncashTransactionValueOfConsiderationReceived1	11000	USD
CY2018	us-gaap	Other Significant Noncash Transaction Value Of Consideration Received1 OtherSignificantNoncashTransactionValueOfConsiderationReceived1	11000	USD
CY2020	us-gaap	Stock Issued1 StockIssued1	387000	USD
CY2019	us-gaap	Stock Issued1 StockIssued1	284000	USD
CY2018	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1350000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1175000	USD
CY2018	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2020	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	1350000	USD
CY2019	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	1175000	USD
CY2018	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
CY2018	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	587000	USD
CY2020	vyne	Interest Received InterestReceived	102000	USD
CY2019	vyne	Interest Received InterestReceived	1359000	USD
CY2018	vyne	Interest Received InterestReceived	1173000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	3941000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	802000	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2020	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	117270000	USD
CY2019	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	0	USD
CY2018	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	0	USD
CY2020	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	5827000	USD
CY2019	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	0	USD
CY2018	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	0	USD
CY2020	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	111443000	USD
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2019	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	0	USD
CY2018	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	0	USD
CY2020	vyne	Non Cash Acquisition Of Business Cash Acquired NonCashAcquisitionOfBusinessCashAcquired	38641000	USD
CY2019	vyne	Non Cash Acquisition Of Business Cash Acquired NonCashAcquisitionOfBusinessCashAcquired	0	USD
CY2018	vyne	Non Cash Acquisition Of Business Cash Acquired NonCashAcquisitionOfBusinessCashAcquired	0	USD
CY2020	vyne	Non Cash Acquisition Of Business Net Assets After Cash Acquired NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired	72802000	USD
CY2019	vyne	Non Cash Acquisition Of Business Net Assets After Cash Acquired NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired	0	USD
CY2018	vyne	Non Cash Acquisition Of Business Net Assets After Cash Acquired NonCashAcquisitionOfBusinessNetAssetsAfterCashAcquired	0	USD
CY2020	us-gaap	Nature Of Operations NatureOfOperations	NATURE OF OPERATIONS<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 4, 2020, the Company changed its corporate name from "Menlo Therapeutics Inc." ("Menlo") to “VYNE Therapeutics Inc.” (the “Company,” “VYNE” or the “combined company”) and changed its ticker symbol on the Nasdaq Global Select Market from "MNLO" to "VYNE." VYNE is a specialty pharmaceutical company focused on developing and commercializing proprietary, innovative and differentiated therapies in dermatology and beyond. The Company is a Delaware corporation, has its principal executive offices in Bridgewater, New Jersey and operates as one business segment.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reverse Merger</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 10, 2019, Menlo, Foamix Pharmaceuticals Ltd. (“Foamix”) and Giants Merger Subsidiary Ltd. (“Merger Sub”), a wholly-owned subsidiary of Menlo, entered into an Agreement and Plan of Merger (as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated as of December 4, 2019, the “Merger Agreement”). Pursuant to the terms of the Merger Agreement, Merger Sub merged with and into Foamix, with Foamix surviving as a wholly-owned subsidiary of Menlo (the “Merger”) on March 9, 2020 (the “Effective Date”).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For accounting purposes, the Merger is treated as a “reverse acquisition” under generally accepted accounting principles in the United States (“U.S. GAAP”) and Foamix is considered the accounting acquirer. Accordingly, upon consummation of the Merger, the historical financial statements of Foamix became the Company’s historical financial statements, and the historical financial statements of Foamix are included in the comparative prior periods. See “Note 3 – Business Combination” for more information on the Merger.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reverse stock split and recasting of per-share amounts </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 10, 2021, our Board of Directors approved a one-for-four reverse stock split of our outstanding shares of common stock. The reverse stock split was effected on February 12, 2021 at 5:00 p.m. Eastern time. At the effective time, every four issued and outstanding shares of our common stock were converted into one share of common stock. No fractional shares were issued in connection with the reverse stock split, and in lieu thereof, each stockholder holding fractional shares was entitled to receive a cash payment (without interest or deduction) from the Company’s transfer agent in an amount equal to such stockholder’s respective pro rata shares of the total net proceeds from the Company’s transfer agent sale of all fractional shares at the then-prevailing prices on the open market. In connection with the reverse stock split, the number of authorized shares of our common stock was also reduced on a one-for-four basis, from 300 million shares to 75 million shares. The par value of each share of common stock remained unchanged. A proportionate adjustment was also made to the maximum number of shares issuable under the Company’s 2019 Equity Incentive Plan, 2018 Omnibus Incentive Plan and 2019 Employee Share Purchase Plan.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless noted, all common shares and per share amounts contained in the consolidated financial statements have been retroactively adjusted to reflect a 1-for-4 reverse stock split.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Products, Product Candidates and Licenses</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Merger, in January 2020, Foamix launched AMZEEQ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (minocycline) topical foam, 4% (“AMZEEQ”), a once-daily topical antibiotic for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. On May 28, 2020, the U.S. Food and Drug Administration (the "FDA") approved ZILXI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (minocycline) topical foam, 1.5% (formerly FMX103, "ZILXI"), for the treatment of inflammatory lesions of rosacea in adults. ZILXI became available in pharmacies nationwide in October 2020. AMZEEQ and ZILXI are the first topical minocycline products approved by the FDA for any condition. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMZEEQ and ZILXI utilize the Company’s proprietary Molecule Stabilizing Technology (MST)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform that is also being used in the development of the Company’s product candidate FCD105, a topical foam comprising minocycline and adapalene for the treatment of acne vulgaris. On June 2, 2020, the Company announced positive results from a Phase II clinical trial evaluating the preliminary safety and efficacy of FCD105 (3% minocycline / 0.3% adapalene foam), the first ever topical minocycline-based combination product, for the treatment of moderate-to-severe acne vulgaris. The Company held an end-of-Phase II meeting with the FDA in the fourth quarter of 2020 and anticipates commencing a Phase III program in 2021. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company was developing serlopitant, a small molecule inhibitor of the neurokinin 1 receptor, or NK1-R, given as a once-daily, oral tablet, for the treatment of pruritus, or itch, associated with various conditions including prurigo nodularis, or PN. On April 6, 2020, the Company announced top line results from two Phase III clinical trials evaluating the safety and efficacy of once-daily oral serlopitant for the treatment of pruritus (itch) associated with PN, studies MTI-105 and MTI-106. Neither study met their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant compared to placebo based on a 4-point improvement responder analysis. The Company does not currently intend to further pursue the development of serlopitant. As a result, the Company recorded a full impairment charge related to the IPR&D and Goodwill assets in its consolidated statement of operations and comprehensive loss. See "Note 3 - Business Combination" for more information.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is actively pursuing opportunities to out-license its products and product candidates to third parties for development and commercialization outside the United States, and entered into a license agreement with Cutia Therapeutics (HK) Limited (“Cutia”) in April 2020. See "Note 4 - Revenue Recognition." The Company has also licensed certain technology under development and licensing agreements to various pharmaceutical companies for development of certain products combining the Company’s foam technology with the licensee’s proprietary drugs.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company launched AMZEEQ in the United States in January 2020 and commenced generating product revenues in the first quarter of 2020. The Company’s activities prior to the commercial launch of AMZEEQ had primarily consisted of developing product candidates, raising capital and performing research and development activities. Since inception, the Company has incurred losses and negative cash flows from operations. For the year ended December 31, 2020, the Company incurred a net loss of $255.6 million and used $137.1 million of cash in operations. As of December 31, 2020, the Company had cash, cash equivalents, restricted cash and investments of $59.4 million and an accumulated deficit of $566.2 million.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company does not successfully commercialize AMZEEQ, ZILXI or any of its future product candidates, it may be unable to achieve profitability. Accordingly, the Company may be required to obtain further funding through public or private debt or equity offerings, or other arrangements. Adequate additional funding may not be available to the Company on acceptable terms, or at all. If the Company is unable to raise capital when needed or on acceptable terms, it may be forced to delay, reduce or eliminate its research and development programs or commercialization and manufacturing efforts. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Merger, the Company was focused on the development and commercialization of serlopitant. Following the receipt of the results of the Phase 3 clinical trials evaluating serlopitant for the treatment of PN and the impact of the COVID-19 pandemic, the Company revised its operating plan to focus on the commercialization of AMZEEQ, ZILXI and its current product candidates. The Company does not currently intend to further pursue the development of serlopitant. In addition, the revised operating plan reflects prudent resource prioritization and allocation management, including the rationalization of research and development spend to focus on existing product candidates.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From January 1, 2021 through January 25, 2021, the Company sold 2,778,012 shares of common stock in "at-the-market" offerings pursuant to the Sales Agreement. The Company received approximately $26.3 million in net proceeds from the sales. Effective as of January 25, 2021, the Company terminated the Sales Agreement and will not make any further sales thereunder. In addition, on January 26, 2021, the Company entered into a Securities Purchase Agreement with certain institutional and accredited investors for the sale of an aggregate of 5,274,261 shares of common stock of the Company, at a purchase price of $9.48 per share in a registered direct offering. The offering was completed on January 28, 2021 and the Company received approximately $46.7 million in net proceeds, after deducting placement agent fees and other offering expenses. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that its existing cash and investments as of December 31, 2020, the net proceeds received from the registered direct offering and the "at-the-market" offerings and projected cash flows from revenues will provide sufficient resources for its operating expense and capital requirements through the end of 2022. However, the amounts and timing of the Company's actual expenditures may vary significantly depending on numerous factors, including the impact of the COVID-19 pandemic, the Company's ability to successfully commercialize AMZEEQ and ZILXI, and any unforeseen cash needs. In addition, the Company may seek additional financing in order to achieve its longer-term strategic plans.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has had a significant impact, both direct and indirect, on global businesses and commerce, including our own operations. For example, our product sales for AMZEEQ and ZILXI have been negatively impacted by office closures as a result of the pandemic. Even as our customers’ offices began to reopen, our access to healthcare providers remained limited </span></div>which dampened sales and negatively impacted our ability to execute our commercial strategy with respect to AMZEEQ and similarly impacted sales of ZILXI, which we launched on October 1, 2020. The future progression of the outbreak and its effects on our business and operations are uncertain. Many patients have chosen not to visit or contact their healthcare providers regarding their skin conditions, which has limited new patient access and conversion. In response to the outbreak, we have taken certain steps to safeguard our employees, healthcare professionals and our other partners. For example, beginning in the first quarter of 2020, our sales force and marketing team were removed from the field and adopted remote and virtual sales activities, including tele-detailing, web-based speaker programs and virtual product education sessions, as needed, in order to meet patients’ needs. In addition, there was a surge in COVID-19 cases in the fourth quarter of 2020 that prompted several regions to re-institute restrictions, which continued to negatively impact our sales force’s ability to access healthcare providers. No assurance can be made that remote sales tactics will be as effective as those used prior to the outbreak of COVID-19. If the activities of our sales force continue to be disrupted or patients elect not to visit their healthcare providers during the pandemic, we may continue to generate less revenue than expected which would have a material adverse effect on our financial results and liquidity as well as hinder our ability to satisfy the minimum revenue covenant contained in our Amended and Restated Credit Agreement, which was amended in August 2020 following an assessment of the impact of the COVID-19 pandemic on our business operations (see "Note 12 - Long-Term Debt" for more information). The future progression of the outbreak and its effects on our business and operations are uncertain.
CY2020	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-255600000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-137100000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	59400000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-566200000	USD
CY2020	us-gaap	Use Of Estimates UseOfEstimates	Use of estimates<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results may differ from those estimates. Significant items subject to such estimates and assumptions include accounting for business combinations, impairments of goodwill and intangible assets and revenue recognition. Actual results could differ from the Company’s estimates.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the COVID-19 pandemic continues to impact the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of the pandemic; the extent to which patients and our sales representatives are able to access healthcare provider offices; the impact on worldwide macroeconomic conditions, including interest rates, employment rates and health insurance coverage; the speed of the anticipated recovery; and governmental and business reactions to the pandemic. The Company's product sales for 2020, particularly during the second and fourth quarters, were negatively impacted by office closures. No assurance can be given that such office closures will not occur again in future periods, and if such closures do occur, or any other circumstance arises such that patients or our sales representatives are restricted in their ability to connect with healthcare providers, our product sales would be negatively impacted. In addition, the Company further assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of December 31, 2020 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s allowance for doubtful accounts and credit losses, inventory and related reserves, impairments of long-lived assets and revenue recognition. The Company recorded impairments of goodwill and certain indefinite-lived intangible assets; however, these were unrelated to the impact of COVID-19 (See "Note 3 - Business Combination" for more information). The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company’s consolidated financial statements in future reporting periods.</span></div>
CY2020Q4	us-gaap	Derivative Number Of Instruments Held DerivativeNumberOfInstrumentsHeld	0	derivativeInstruments
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	4500000	USD
CY2020	vyne	Adjustments To Supplemental Proforma Acceleration Of Stock Based Compensation AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation	7199000	USD
CY2019	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2018	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2020Q2	vyne	Contingent Stock Right Shares Conversion ContingentStockRightSharesConversion	1.2082
CY2020Q2	vyne	Business Combination Effective Exchange Ratio BusinessCombinationEffectiveExchangeRatio	1.8006
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	Concentration of credit risks<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents, restricted cash, bank deposits, marketable securities and accounts receivables. The Company deposits cash and cash equivalents with highly rated financial institutions and, as a matter of policy, limits the amounts of credit exposure to any single financial institution. In addition, all marketable securities carry a high rating or are government insured. The Company has not experienced any material credit losses in these accounts and does not believe it is exposed to significant credit risk on these instruments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2020, the Company's three largest customers collectively represented 96% of product revenue and 90% of accounts receivable.</span></div>
CY2020Q2	vyne	Contingent Stock Right Shares Conversion ContingentStockRightSharesConversion	1.2082
CY2020Q2	vyne	Business Combination Effective Exchange Ratio BusinessCombinationEffectiveExchangeRatio	1.8006
CY2020Q2	vyne	Shares Issued Upon Conversion Of Common Stock Rights Per Agreement SharesIssuedUponConversionOfCommonStockRightsPerAgreement	74544413	shares
CY2020Q2	vyne	Post Merger Parent Ownership By Pre Merger Subsidiary Shareholders PostMergerParentOwnershipByPreMergerSubsidiaryShareholders	0.82
CY2020Q2	vyne	Post Merger Parent Ownership By Pre Merger Parent Stockholders PostMergerParentOwnershipByPreMergerParentStockholders	0.18
CY2020	us-gaap	Business Combination Consideration Transferred Equity Interests Issued And Issuable BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable	123757000	USD
CY2020	vyne	Business Combination Consideration Transferred Conversion Of Acquirer Equity Awards BusinessCombinationConsiderationTransferredConversionOfAcquirerEquityAwards	7322000	USD
CY2020	vyne	Business Combination Consideration Transferred Gross BusinessCombinationConsiderationTransferredGross	131079000	USD
CY2020Q1	vyne	Business Combination Acquiree Common Stock Rights Converted To Common Stock BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock	19600000	USD
CY2020Q1	vyne	Business Combination Acquiree Common Stock Rights Converted To Common Stock BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock	19600000	USD
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	4500000	USD
CY2018	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020Q1	vyne	Business Combination Acquiree Common Stock Rights Converted To Common Stock BusinessCombinationAcquireeCommonStockRightsConvertedToCommonStock	19600000	USD
CY2020Q2	vyne	Contingent Stock Right Shares Conversion ContingentStockRightSharesConversion	1.2082
CY2020Q2	vyne	Business Combination Effective Exchange Ratio BusinessCombinationEffectiveExchangeRatio	1.8006
CY2020Q2	vyne	Shares Issued Upon Conversion Of Common Stock Rights Per Agreement SharesIssuedUponConversionOfCommonStockRightsPerAgreement	74500000	shares
CY2020Q2	vyne	Post Merger Parent Ownership By Pre Merger Subsidiary Shareholders PostMergerParentOwnershipByPreMergerSubsidiaryShareholders	0.82
CY2020Q2	vyne	Post Merger Parent Ownership By Pre Merger Parent Stockholders PostMergerParentOwnershipByPreMergerParentStockholders	0.18
CY2020Q2	vyne	Contingent Stock Consideration Remeasurement Gain Loss ContingentStockConsiderationRemeasurementGainLoss	-84700000	USD
CY2020Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	104400000	USD
CY2020Q2	vyne	Shares Issued Upon Conversion Of Common Stock Rights Per Agreement SharesIssuedUponConversionOfCommonStockRightsPerAgreement	74544413	shares
CY2020Q2	us-gaap	Share Price SharePrice	1.40
CY2019	vyne	Adjustments To Supplemental Proforma Acceleration Of Stock Based Compensation AdjustmentsToSupplementalProformaAccelerationOfStockBasedCompensation	0	USD
CY2020	us-gaap	Business Combination Pro Forma Information Revenue Of Acquiree Since Acquisition Date Actual BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual	0	USD
CY2020	us-gaap	Business Combination Pro Forma Information Earnings Or Loss Of Acquiree Since Acquisition Date Actual BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual	24517000	USD
CY2020	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	20993000	USD
CY2019	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	443000	USD
CY2020	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-252951000	USD
CY2019	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-161967000	USD
CY2020	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-7.53
CY2020	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	-7.53
CY2020Q4	vyne	Derivate Costs For Year DerivateCostsForYear	0	USD
CY2019	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	-11.19
CY2019	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-11.19
CY2020	vyne	Adjustments To Supplemental Proforma Transaction Costs AdjustmentsToSupplementalProformaTransactionCosts	14931000	USD
CY2019	vyne	Adjustments To Supplemental Proforma Transaction Costs AdjustmentsToSupplementalProformaTransactionCosts	0	USD
CY2020Q4	vyne	Estimate Of Product Return Rate Maximum EstimateOfProductReturnRateMaximum	0.03
CY2020Q4	us-gaap	Marketable Securities MarketableSecurities	1027000	USD
CY2019Q4	us-gaap	Marketable Securities MarketableSecurities	16680000	USD
CY2020	vyne	Adjustments To Supplemental Proforma Combined Results Of Operations AdjustmentsToSupplementalProformaCombinedResultsOfOperations	22130000	USD
CY2019	vyne	Adjustments To Supplemental Proforma Combined Results Of Operations AdjustmentsToSupplementalProformaCombinedResultsOfOperations	0	USD
CY2020	vyne	Revenue Recognition Distribution Trade Discounts And Allowances RevenueRecognitionDistributionTradeDiscountsAndAllowances	39500000	USD
CY2020Q4	vyne	Estimate Of Product Return Rate Minimum EstimateOfProductReturnRateMinimum	0.02
CY2020	vyne	Derivative Maximum Term Of Contract DerivativeMaximumTermOfContract	P1Y
CY2018Q4	us-gaap	Derivative Amount Of Hedged Item DerivativeAmountOfHedgedItem	0	USD
CY2019Q4	us-gaap	Derivative Amount Of Hedged Item DerivativeAmountOfHedgedItem	0	USD
CY2020Q4	us-gaap	Derivative Amount Of Hedged Item DerivativeAmountOfHedgedItem	0	USD
CY2019Q4	vyne	Foreign Exchange Risk Lien On Checking Account For Bank Guarantees Granted For Hedging Transactions ForeignExchangeRiskLienOnCheckingAccountForBankGuaranteesGrantedForHedgingTransactions	300000	USD
CY2020Q4	vyne	Foreign Exchange Risk Lien On Checking Account For Bank Guarantees Granted For Hedging Transactions ForeignExchangeRiskLienOnCheckingAccountForBankGuaranteesGrantedForHedgingTransactions	300000	USD
CY2019Q4	vyne	Foreign Exchange Risk Lien On Marketable Securities For Bank Guarantees Granted For Hedging Transactions ForeignExchangeRiskLienOnMarketableSecuritiesForBankGuaranteesGrantedForHedgingTransactions	300000	USD
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	1027000	USD
CY2019Q4	us-gaap	Short Term Investments ShortTermInvestments	16680000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	15660000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	15656000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	4000	USD
CY2020	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0	USD
CY2020	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	38500000	USD
CY2019	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	49800000	USD
CY2020Q4	us-gaap	Restricted Investments RestrictedInvestments	0	USD
CY2019Q4	us-gaap	Restricted Investments RestrictedInvestments	400000	USD
CY2020	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2019	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2020Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	4042000	USD
CY2019Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	500000	USD
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	662000	USD
CY2019Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	0	USD
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2700000	USD
CY2019	us-gaap	Proceeds From Sale Of Property Held For Sale ProceedsFromSaleOfPropertyHeldForSale	16000	USD
CY2019Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	856000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	7404000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	1356000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	998000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4117000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	443000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1232000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	555000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2885000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	300000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	400000	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	300000	USD
CY2020	us-gaap	Proceeds From Sale Of Property Held For Sale ProceedsFromSaleOfPropertyHeldForSale	2100000	USD
CY2018	us-gaap	Proceeds From Sale Of Property Held For Sale ProceedsFromSaleOfPropertyHeldForSale	42000	USD
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-2000	USD
CY2018	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-2000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P3Y
CY2020	vyne	Vehicle Lease Prepayment Period VehicleLeasePrepaymentPeriod	P3M
CY2020	us-gaap	Operating Lease Variable Lease Income OperatingLeaseVariableLeaseIncome	35000	USD
CY2019	us-gaap	Operating Lease Variable Lease Income OperatingLeaseVariableLeaseIncome	45000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1583000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1694000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1610000	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1745000	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y11M15D
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y11M4D
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1310
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0608
CY2018	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	900000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	913000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	761000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	151000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1825000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	215000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1610000	USD
CY2020Q4	vyne	Restricted Investments To Secure Lease Agreements RestrictedInvestmentsToSecureLeaseAgreements	600000	USD
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	800000	USD
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	200000	USD
CY2018	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000	USD
CY2019Q3	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	1100000	USD
CY2020	us-gaap	Interest Expense Debt InterestExpenseDebt	3900000	USD
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	500000	USD
CY2019	us-gaap	Interest Expense Debt InterestExpenseDebt	800000	USD
CY2019	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	100000	USD
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	300000	USD
CY2018Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	75400000	USD
CY2018Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	16100000	USD
CY2020Q2	vyne	Contingent Stock Right Shares Conversion ContingentStockRightSharesConversion	1.2082
CY2020Q2	vyne	Business Combination Effective Exchange Ratio BusinessCombinationEffectiveExchangeRatio	1.8006
CY2020Q2	vyne	Contingent Stock Right Shares Conversion ContingentStockRightSharesConversion	1.2082
CY2020Q2	vyne	Business Combination Effective Exchange Ratio BusinessCombinationEffectiveExchangeRatio	1.8006
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	700000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	829173	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	38.44
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	132352	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	26.92
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	8371	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	41.08
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	899293	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	23.24
	vyne	Share Based Compensation Arrangement By Share Based Payment Award Options Conversions In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversionsInPeriod	-1944022	shares
	vyne	Share Based Compensation Arrangements By Share Based Payment Award Options Conversions In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConversionsInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	925528	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.72
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	44188	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.48
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	259257	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	9.40
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	143903	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	29.48
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4274649	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.36
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2708158	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	15.90
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y11M19D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y4M2D
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	6700000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	200000	USD
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	100000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	18100000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	4895000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	5320000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-255826000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-95354000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-73951000	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-258000	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-176000	USD
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	212000	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	5000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-253000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-176000	USD
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	212000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0035
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0
CY2020	vyne	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development And Contingent Stock Right Remeasurement Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentAndContingentStockRightRemeasurementPercent	-0.1142
CY2019	vyne	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development And Contingent Stock Right Remeasurement Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentAndContingentStockRightRemeasurementPercent	0
CY2018	vyne	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development And Contingent Stock Right Remeasurement Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentAndContingentStockRightRemeasurementPercent	0
CY2020	vyne	Effective Income Tax Rate Reconciliation Nondeductible Expense Transaction Costs Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostsPercent	-0.0107
CY2019	vyne	Effective Income Tax Rate Reconciliation Nondeductible Expense Transaction Costs Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostsPercent	0
CY2018	vyne	Effective Income Tax Rate Reconciliation Nondeductible Expense Transaction Costs Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTransactionCostsPercent	0
CY2020	vyne	Effective Income Tax Rate Reconciliation Gain On Intangible Assets Percent EffectiveIncomeTaxRateReconciliationGainOnIntangibleAssetsPercent	-0.1465
CY2019	vyne	Effective Income Tax Rate Reconciliation Gain On Intangible Assets Percent EffectiveIncomeTaxRateReconciliationGainOnIntangibleAssetsPercent	0
CY2018	vyne	Effective Income Tax Rate Reconciliation Gain On Intangible Assets Percent EffectiveIncomeTaxRateReconciliationGainOnIntangibleAssetsPercent	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.0616
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2421
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2307
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0200
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0200
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.0027
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.0140
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.0022
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0010
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0019
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0029
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3100000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	700000	USD
CY2020Q4	us-gaap	Decrease In Unrecognized Tax Benefits Is Reasonably Possible DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible	500000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	55514000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	59241000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	7387000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	10089000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4903000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1446000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2325000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	225000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	70129000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	71001000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	69743000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	71001000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	41000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	345000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	0	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	386000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	69700000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	71000000.0	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-1300000	USD
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	23100000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	890000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions	176000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	714000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	2354000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	273000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	258000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3083000	USD
CY2020Q4	vyne	Liquidation Of Subsidiary Intellectual Property Acquired Taxable Gain LiquidationOfSubsidiaryIntellectualPropertyAcquiredTaxableGain	163000000.0	USD
CY2020Q1	us-gaap	Revenues Revenues	1750000	USD
CY2020Q2	us-gaap	Revenues Revenues	11688000	USD
CY2020Q3	us-gaap	Revenues Revenues	3269000	USD
CY2020Q4	us-gaap	Revenues Revenues	4286000	USD
CY2019Q1	us-gaap	Revenues Revenues	308000	USD
CY2019Q2	us-gaap	Revenues Revenues	0	USD
CY2019Q3	us-gaap	Revenues Revenues	0	USD
CY2019Q4	us-gaap	Revenues Revenues	135000	USD
CY2020Q1	us-gaap	Cost Of Revenue CostOfRevenue	41639000	USD
CY2020Q2	us-gaap	Cost Of Revenue CostOfRevenue	178865000	USD
CY2020Q3	us-gaap	Cost Of Revenue CostOfRevenue	26760000	USD
CY2020Q4	us-gaap	Cost Of Revenue CostOfRevenue	24883000	USD
CY2019Q1	us-gaap	Cost Of Revenue CostOfRevenue	16192000	USD
CY2019Q2	us-gaap	Cost Of Revenue CostOfRevenue	19359000	USD
CY2019Q3	us-gaap	Cost Of Revenue CostOfRevenue	23199000	USD
CY2019Q4	us-gaap	Cost Of Revenue CostOfRevenue	0	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-39889000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-167177000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-23491000	USD
CY2020Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-21989000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-15884000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-19359000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-23199000	USD
CY2019Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-37431000	USD
CY2020Q1	vyne	Earnings Per Share Basic And Diluted Before Reverse Stock Split EarningsPerShareBasicAndDilutedBeforeReverseStockSplit	0.95
CY2020Q2	vyne	Earnings Per Share Basic And Diluted Before Reverse Stock Split EarningsPerShareBasicAndDilutedBeforeReverseStockSplit	1.21
CY2020Q3	vyne	Earnings Per Share Basic And Diluted Before Reverse Stock Split EarningsPerShareBasicAndDilutedBeforeReverseStockSplit	0.15
CY2020Q4	vyne	Earnings Per Share Basic And Diluted Before Reverse Stock Split EarningsPerShareBasicAndDilutedBeforeReverseStockSplit	0.14
CY2019Q1	vyne	Earnings Per Share Basic And Diluted Before Reverse Stock Split EarningsPerShareBasicAndDilutedBeforeReverseStockSplit	0.47
CY2019Q2	vyne	Earnings Per Share Basic And Diluted Before Reverse Stock Split EarningsPerShareBasicAndDilutedBeforeReverseStockSplit	0.59
CY2019Q3	vyne	Earnings Per Share Basic And Diluted Before Reverse Stock Split EarningsPerShareBasicAndDilutedBeforeReverseStockSplit	0.7
CY2019Q4	vyne	Earnings Per Share Basic And Diluted Before Reverse Stock Split EarningsPerShareBasicAndDilutedBeforeReverseStockSplit	1.04
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	3.79
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	4.83
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.59
CY2020Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.55
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	1.89
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	2.36
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	2.79
CY2019Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	4.17
CY2020Q4	vyne	Business Combination Effective Exchange Ratio BusinessCombinationEffectiveExchangeRatio	0.5924
CY2020Q2	vyne	Business Combination Effective Exchange Ratio BusinessCombinationEffectiveExchangeRatio	1.8006

Files In Submission

Name	View Source	Status
0001566044-21-000010-index-headers.html	Edgar Link	pending
0001566044-21-000010-index.html	Edgar Link	pending
0001566044-21-000010.txt	Edgar Link	pending
0001566044-21-000010-xbrl.zip	Edgar Link	pending
a1011c-formofrsuagreement2.htm	Edgar Link	pending
exhibit211listofsubsidiari.htm	Edgar Link	pending
exhibit231consentus.htm	Edgar Link	pending
exhibit232consentisr.htm	Edgar Link	pending
exhibit31vynecertificateof.htm	Edgar Link	pending
exhibit41.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vyne-20201231.htm	Edgar Link	pending
vyne-20201231.xsd	Edgar Link	pending
vyne-20201231xexx311.htm	Edgar Link	pending
vyne-20201231xexx312.htm	Edgar Link	pending
vyne-20201231xexx321.htm	Edgar Link	pending
vyne-20201231xexx322.htm	Edgar Link	pending
vyne-20201231_cal.xml	Edgar Link	unprocessable
vyne-20201231_def.xml	Edgar Link	unprocessable
vyne-20201231_g1.jpg	Edgar Link	pending
vyne-20201231_g2.jpg	Edgar Link	pending
vyne-20201231_g3.jpg	Edgar Link	pending
vyne-20201231_htm.xml	Edgar Link	completed
vyne-20201231_lab.xml	Edgar Link	unprocessable
vyne-20201231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VYNE
VYNE Therapeutics Inc. Stock $vyne

2020 Q4 Form 10-K Financial Statement

#000156604421000010 Filed on March 04, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VYNE VYNE Therapeutics Inc. Stock $vyne

2020 Q4 Form 10-K Financial Statement

#000156604421000010 Filed on March 04, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VYNE
VYNE Therapeutics Inc. Stock $vyne